Cargando…

Evaluation of productivity in Iranian pharmaceutical companies: A DEA-based Malmquist approach and panel data analysis

OBJECTIVE: In this study, we aimed to assess comparative productivity of 21 pharmaceutical companies in Iran during 2000–2013. METHODS: To evaluate the productivity trend of pharmaceutical companies in Iran, we used data envelopment analysis-based Malmquist index. “Total assets” and “capital stock”...

Descripción completa

Detalles Bibliográficos
Autores principales: Varmaghani, Mehdi, Meshkini, Amir Hashemi, Farzadfar, Farshad, Yousefi, Mehdi, Yaghoubifard, Saeed, Varahrami, Vida, Darzi, Ehsan Rezaei, Anabi, Majid, Kebriaeezadeh, Abbas, Zekri, Hedieh-Sadat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418136/
https://www.ncbi.nlm.nih.gov/pubmed/25984541
http://dx.doi.org/10.4103/2279-042X.155750
_version_ 1782369440348766208
author Varmaghani, Mehdi
Meshkini, Amir Hashemi
Farzadfar, Farshad
Yousefi, Mehdi
Yaghoubifard, Saeed
Varahrami, Vida
Darzi, Ehsan Rezaei
Anabi, Majid
Kebriaeezadeh, Abbas
Zekri, Hedieh-Sadat
author_facet Varmaghani, Mehdi
Meshkini, Amir Hashemi
Farzadfar, Farshad
Yousefi, Mehdi
Yaghoubifard, Saeed
Varahrami, Vida
Darzi, Ehsan Rezaei
Anabi, Majid
Kebriaeezadeh, Abbas
Zekri, Hedieh-Sadat
author_sort Varmaghani, Mehdi
collection PubMed
description OBJECTIVE: In this study, we aimed to assess comparative productivity of 21 pharmaceutical companies in Iran during 2000–2013. METHODS: To evaluate the productivity trend of pharmaceutical companies in Iran, we used data envelopment analysis-based Malmquist index. “Total assets” and “capital stock” as inputs and “net sales” and “net profit” as outputs extracted from Tehran stock exchange, were selected to be included in the analysis. This method provides the possibility for analyzing the performance of each company in term of productivity changes over time. We also used an estimation generalized least square panel data model to identify the factors that might affect productivity of pharmaceutical companies in Iran using EViews 7 and Deep 2.1 software. FINDINGS: The mean total productivity during all years of the study was 0.9829, which indicates the improvement in their overall productivity. The results, over the 13-year period, indicated that the range of productivity changes in pharmaceutical companies, that were included in this study, was between 0.884 and 1.098. Panel data model indicated that age of company could positively (t = 4.765978, P < 0.001) and being located in cities other than Tehran (the capital) could negatively (t = −5.369549, P < 0.001) affect the productivity of pharmaceutical companies. The analysis showed the new policy (brand-generic scheme) and also the type of ownership did not have a significant effect on the productivity of pharmaceutical companies. CONCLUSION: In this study, pharmaceutical productivity trends were fluctuated that could be due to the sub-optimal attention of policy makers and managers of pharmaceutical companies toward long-term strategic planning, focusing on productivity improvement.
format Online
Article
Text
id pubmed-4418136
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-44181362015-05-15 Evaluation of productivity in Iranian pharmaceutical companies: A DEA-based Malmquist approach and panel data analysis Varmaghani, Mehdi Meshkini, Amir Hashemi Farzadfar, Farshad Yousefi, Mehdi Yaghoubifard, Saeed Varahrami, Vida Darzi, Ehsan Rezaei Anabi, Majid Kebriaeezadeh, Abbas Zekri, Hedieh-Sadat J Res Pharm Pract Original Article OBJECTIVE: In this study, we aimed to assess comparative productivity of 21 pharmaceutical companies in Iran during 2000–2013. METHODS: To evaluate the productivity trend of pharmaceutical companies in Iran, we used data envelopment analysis-based Malmquist index. “Total assets” and “capital stock” as inputs and “net sales” and “net profit” as outputs extracted from Tehran stock exchange, were selected to be included in the analysis. This method provides the possibility for analyzing the performance of each company in term of productivity changes over time. We also used an estimation generalized least square panel data model to identify the factors that might affect productivity of pharmaceutical companies in Iran using EViews 7 and Deep 2.1 software. FINDINGS: The mean total productivity during all years of the study was 0.9829, which indicates the improvement in their overall productivity. The results, over the 13-year period, indicated that the range of productivity changes in pharmaceutical companies, that were included in this study, was between 0.884 and 1.098. Panel data model indicated that age of company could positively (t = 4.765978, P < 0.001) and being located in cities other than Tehran (the capital) could negatively (t = −5.369549, P < 0.001) affect the productivity of pharmaceutical companies. The analysis showed the new policy (brand-generic scheme) and also the type of ownership did not have a significant effect on the productivity of pharmaceutical companies. CONCLUSION: In this study, pharmaceutical productivity trends were fluctuated that could be due to the sub-optimal attention of policy makers and managers of pharmaceutical companies toward long-term strategic planning, focusing on productivity improvement. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4418136/ /pubmed/25984541 http://dx.doi.org/10.4103/2279-042X.155750 Text en Copyright: © Journal of Research in Pharmacy Practice http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Varmaghani, Mehdi
Meshkini, Amir Hashemi
Farzadfar, Farshad
Yousefi, Mehdi
Yaghoubifard, Saeed
Varahrami, Vida
Darzi, Ehsan Rezaei
Anabi, Majid
Kebriaeezadeh, Abbas
Zekri, Hedieh-Sadat
Evaluation of productivity in Iranian pharmaceutical companies: A DEA-based Malmquist approach and panel data analysis
title Evaluation of productivity in Iranian pharmaceutical companies: A DEA-based Malmquist approach and panel data analysis
title_full Evaluation of productivity in Iranian pharmaceutical companies: A DEA-based Malmquist approach and panel data analysis
title_fullStr Evaluation of productivity in Iranian pharmaceutical companies: A DEA-based Malmquist approach and panel data analysis
title_full_unstemmed Evaluation of productivity in Iranian pharmaceutical companies: A DEA-based Malmquist approach and panel data analysis
title_short Evaluation of productivity in Iranian pharmaceutical companies: A DEA-based Malmquist approach and panel data analysis
title_sort evaluation of productivity in iranian pharmaceutical companies: a dea-based malmquist approach and panel data analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418136/
https://www.ncbi.nlm.nih.gov/pubmed/25984541
http://dx.doi.org/10.4103/2279-042X.155750
work_keys_str_mv AT varmaghanimehdi evaluationofproductivityiniranianpharmaceuticalcompaniesadeabasedmalmquistapproachandpaneldataanalysis
AT meshkiniamirhashemi evaluationofproductivityiniranianpharmaceuticalcompaniesadeabasedmalmquistapproachandpaneldataanalysis
AT farzadfarfarshad evaluationofproductivityiniranianpharmaceuticalcompaniesadeabasedmalmquistapproachandpaneldataanalysis
AT yousefimehdi evaluationofproductivityiniranianpharmaceuticalcompaniesadeabasedmalmquistapproachandpaneldataanalysis
AT yaghoubifardsaeed evaluationofproductivityiniranianpharmaceuticalcompaniesadeabasedmalmquistapproachandpaneldataanalysis
AT varahramivida evaluationofproductivityiniranianpharmaceuticalcompaniesadeabasedmalmquistapproachandpaneldataanalysis
AT darziehsanrezaei evaluationofproductivityiniranianpharmaceuticalcompaniesadeabasedmalmquistapproachandpaneldataanalysis
AT anabimajid evaluationofproductivityiniranianpharmaceuticalcompaniesadeabasedmalmquistapproachandpaneldataanalysis
AT kebriaeezadehabbas evaluationofproductivityiniranianpharmaceuticalcompaniesadeabasedmalmquistapproachandpaneldataanalysis
AT zekrihediehsadat evaluationofproductivityiniranianpharmaceuticalcompaniesadeabasedmalmquistapproachandpaneldataanalysis